Intravenous buprenorphine

Effects of 2 to 16 mg doses in nondependent opioid abusers

K. L. Preston, Annie Umbricht, M. A. Huestis, E. J. Cone

Research output: Contribution to journalArticle

Abstract

Buprenorphine (BUP), a partial agonist, produces prototypic opioid-like effects and is an effective maintenance therapy for opioid dependence. Escalating IV BUP doses (2, 4, 8, 12 & 16 mg), sublingual (SL) BUP 12 mg, and an IV/SL placebo were tested in 7 sessions in 6 nondependent opioid abusers living on a research unit. Physiological, subjective and psychomotor performance measures and blood specimens were collected for up to 72 hours after drug administration. BUP significantly increased systolic blood pressure with no other significant changes in blood pressure, heart rate or oxygen (02) saturation among the 7 drug conditions. Mean maximum decrease in 02 saturation was greatest for 8-mg IV. BUP produced positive mood effects, though with substantial inter-subject variability. BUP decreased performance scores at all doses. Onset of effects occurred earlier following IV than SL administration. Peak IV effects occurred between 0.25 and 3 hrs; peak SL effects occurred at 3 to 7 hrs. Duration of effects varied among the outcome measures. The dose-response curves were flat for most parameters. In contrast, BUP plasma concentrations increased proportionately with IV dose. Bioavailability of SL BUP was approximately 35%. Mean time to peak plasma concentrations was 5-10 min for IV doses and 30 min for 12-mg SL. Generally, side effects were mild except in one participant who was discontinued after the 12-mg IV dose because of severe nausea. BUP appears to have a ceiling on pharmacodynamic effects in the presence of dose-proportionate plasma levels and has a high safety margin when given by the IV route and in the absence of other drugs.

Original languageEnglish (US)
JournalClinical Pharmacology and Therapeutics
Volume69
Issue number2
StatePublished - 2001
Externally publishedYes

Fingerprint

Buprenorphine
Opioid Analgesics
Blood Pressure
Sublingual Administration
Pharmaceutical Preparations
Psychomotor Performance
Nausea
Biological Availability
Heart Rate
Placebos
Outcome Assessment (Health Care)
Oxygen
Safety

ASJC Scopus subject areas

  • Pharmacology

Cite this

Intravenous buprenorphine : Effects of 2 to 16 mg doses in nondependent opioid abusers. / Preston, K. L.; Umbricht, Annie; Huestis, M. A.; Cone, E. J.

In: Clinical Pharmacology and Therapeutics, Vol. 69, No. 2, 2001.

Research output: Contribution to journalArticle

@article{5c0b8be202854d29bd19c046282a11ca,
title = "Intravenous buprenorphine: Effects of 2 to 16 mg doses in nondependent opioid abusers",
abstract = "Buprenorphine (BUP), a partial agonist, produces prototypic opioid-like effects and is an effective maintenance therapy for opioid dependence. Escalating IV BUP doses (2, 4, 8, 12 & 16 mg), sublingual (SL) BUP 12 mg, and an IV/SL placebo were tested in 7 sessions in 6 nondependent opioid abusers living on a research unit. Physiological, subjective and psychomotor performance measures and blood specimens were collected for up to 72 hours after drug administration. BUP significantly increased systolic blood pressure with no other significant changes in blood pressure, heart rate or oxygen (02) saturation among the 7 drug conditions. Mean maximum decrease in 02 saturation was greatest for 8-mg IV. BUP produced positive mood effects, though with substantial inter-subject variability. BUP decreased performance scores at all doses. Onset of effects occurred earlier following IV than SL administration. Peak IV effects occurred between 0.25 and 3 hrs; peak SL effects occurred at 3 to 7 hrs. Duration of effects varied among the outcome measures. The dose-response curves were flat for most parameters. In contrast, BUP plasma concentrations increased proportionately with IV dose. Bioavailability of SL BUP was approximately 35{\%}. Mean time to peak plasma concentrations was 5-10 min for IV doses and 30 min for 12-mg SL. Generally, side effects were mild except in one participant who was discontinued after the 12-mg IV dose because of severe nausea. BUP appears to have a ceiling on pharmacodynamic effects in the presence of dose-proportionate plasma levels and has a high safety margin when given by the IV route and in the absence of other drugs.",
author = "Preston, {K. L.} and Annie Umbricht and Huestis, {M. A.} and Cone, {E. J.}",
year = "2001",
language = "English (US)",
volume = "69",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Intravenous buprenorphine

T2 - Effects of 2 to 16 mg doses in nondependent opioid abusers

AU - Preston, K. L.

AU - Umbricht, Annie

AU - Huestis, M. A.

AU - Cone, E. J.

PY - 2001

Y1 - 2001

N2 - Buprenorphine (BUP), a partial agonist, produces prototypic opioid-like effects and is an effective maintenance therapy for opioid dependence. Escalating IV BUP doses (2, 4, 8, 12 & 16 mg), sublingual (SL) BUP 12 mg, and an IV/SL placebo were tested in 7 sessions in 6 nondependent opioid abusers living on a research unit. Physiological, subjective and psychomotor performance measures and blood specimens were collected for up to 72 hours after drug administration. BUP significantly increased systolic blood pressure with no other significant changes in blood pressure, heart rate or oxygen (02) saturation among the 7 drug conditions. Mean maximum decrease in 02 saturation was greatest for 8-mg IV. BUP produced positive mood effects, though with substantial inter-subject variability. BUP decreased performance scores at all doses. Onset of effects occurred earlier following IV than SL administration. Peak IV effects occurred between 0.25 and 3 hrs; peak SL effects occurred at 3 to 7 hrs. Duration of effects varied among the outcome measures. The dose-response curves were flat for most parameters. In contrast, BUP plasma concentrations increased proportionately with IV dose. Bioavailability of SL BUP was approximately 35%. Mean time to peak plasma concentrations was 5-10 min for IV doses and 30 min for 12-mg SL. Generally, side effects were mild except in one participant who was discontinued after the 12-mg IV dose because of severe nausea. BUP appears to have a ceiling on pharmacodynamic effects in the presence of dose-proportionate plasma levels and has a high safety margin when given by the IV route and in the absence of other drugs.

AB - Buprenorphine (BUP), a partial agonist, produces prototypic opioid-like effects and is an effective maintenance therapy for opioid dependence. Escalating IV BUP doses (2, 4, 8, 12 & 16 mg), sublingual (SL) BUP 12 mg, and an IV/SL placebo were tested in 7 sessions in 6 nondependent opioid abusers living on a research unit. Physiological, subjective and psychomotor performance measures and blood specimens were collected for up to 72 hours after drug administration. BUP significantly increased systolic blood pressure with no other significant changes in blood pressure, heart rate or oxygen (02) saturation among the 7 drug conditions. Mean maximum decrease in 02 saturation was greatest for 8-mg IV. BUP produced positive mood effects, though with substantial inter-subject variability. BUP decreased performance scores at all doses. Onset of effects occurred earlier following IV than SL administration. Peak IV effects occurred between 0.25 and 3 hrs; peak SL effects occurred at 3 to 7 hrs. Duration of effects varied among the outcome measures. The dose-response curves were flat for most parameters. In contrast, BUP plasma concentrations increased proportionately with IV dose. Bioavailability of SL BUP was approximately 35%. Mean time to peak plasma concentrations was 5-10 min for IV doses and 30 min for 12-mg SL. Generally, side effects were mild except in one participant who was discontinued after the 12-mg IV dose because of severe nausea. BUP appears to have a ceiling on pharmacodynamic effects in the presence of dose-proportionate plasma levels and has a high safety margin when given by the IV route and in the absence of other drugs.

UR - http://www.scopus.com/inward/record.url?scp=0012212181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0012212181&partnerID=8YFLogxK

M3 - Article

VL - 69

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -